Concepts (163)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 23 | 2022 | 1109 | 4.780 |
Why?
|
| Naltrexone | 7 | 2021 | 195 | 3.070 |
Why?
|
| Catechol O-Methyltransferase | 4 | 2022 | 31 | 2.300 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 5 | 2021 | 82 | 2.130 |
Why?
|
| Receptors, Opioid, mu | 5 | 2021 | 70 | 1.680 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2020 | 627 | 1.600 |
Why?
|
| Narcotic Antagonists | 4 | 2021 | 184 | 1.530 |
Why?
|
| Cues | 14 | 2022 | 654 | 1.530 |
Why?
|
| Marijuana Abuse | 8 | 2019 | 251 | 1.470 |
Why?
|
| Alcohol Drinking | 13 | 2020 | 805 | 1.210 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2019 | 208 | 1.040 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2019 | 435 | 1.020 |
Why?
|
| Brain | 14 | 2019 | 2175 | 1.000 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2022 | 2222 | 0.880 |
Why?
|
| Pharmacogenomic Variants | 3 | 2017 | 15 | 0.880 |
Why?
|
| Flumazenil | 2 | 2013 | 23 | 0.850 |
Why?
|
| Reward | 5 | 2020 | 201 | 0.830 |
Why?
|
| Cyclohexanecarboxylic Acids | 2 | 2013 | 60 | 0.820 |
Why?
|
| Amines | 2 | 2013 | 98 | 0.800 |
Why?
|
| Aripiprazole | 2 | 2017 | 43 | 0.770 |
Why?
|
| Alcohol Deterrents | 2 | 2018 | 86 | 0.760 |
Why?
|
| Cognition | 3 | 2018 | 512 | 0.750 |
Why?
|
| Dopamine Agonists | 2 | 2017 | 68 | 0.750 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 163 | 0.720 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 301 | 0.700 |
Why?
|
| Receptor, Cannabinoid, CB1 | 4 | 2012 | 68 | 0.650 |
Why?
|
| Dopamine | 2 | 2022 | 474 | 0.650 |
Why?
|
| Functional Neuroimaging | 3 | 2018 | 82 | 0.610 |
Why?
|
| Craving | 3 | 2019 | 200 | 0.590 |
Why?
|
| Cannabis | 1 | 2018 | 115 | 0.580 |
Why?
|
| Dopamine Agents | 1 | 2016 | 56 | 0.560 |
Why?
|
| Brain Mapping | 4 | 2017 | 531 | 0.560 |
Why?
|
| Cocaine | 1 | 2021 | 555 | 0.540 |
Why?
|
| Young Adult | 17 | 2020 | 5708 | 0.530 |
Why?
|
| Adult | 25 | 2021 | 21375 | 0.530 |
Why?
|
| Motivation | 6 | 2020 | 561 | 0.520 |
Why?
|
| Amidohydrolases | 3 | 2009 | 60 | 0.500 |
Why?
|
| Nicotine | 1 | 2018 | 350 | 0.500 |
Why?
|
| Glutamic Acid | 5 | 2019 | 332 | 0.500 |
Why?
|
| Humans | 37 | 2022 | 68525 | 0.500 |
Why?
|
| Male | 28 | 2021 | 37281 | 0.490 |
Why?
|
| Female | 27 | 2021 | 38015 | 0.480 |
Why?
|
| Genetic Variation | 2 | 2012 | 220 | 0.480 |
Why?
|
| Quinoxalines | 1 | 2014 | 78 | 0.470 |
Why?
|
| Genotype | 6 | 2020 | 785 | 0.470 |
Why?
|
| Benzazepines | 1 | 2014 | 104 | 0.460 |
Why?
|
| Marijuana Smoking | 2 | 2019 | 108 | 0.460 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2018 | 785 | 0.460 |
Why?
|
| Nicotinic Agonists | 1 | 2014 | 111 | 0.450 |
Why?
|
| Prefrontal Cortex | 2 | 2016 | 639 | 0.450 |
Why?
|
| Smoking | 2 | 2018 | 1449 | 0.430 |
Why?
|
| Substance-Related Disorders | 1 | 2021 | 1241 | 0.400 |
Why?
|
| Alcohol-Related Disorders | 1 | 2012 | 95 | 0.400 |
Why?
|
| Treatment Outcome | 7 | 2021 | 7028 | 0.390 |
Why?
|
| Ethanol | 4 | 2022 | 892 | 0.390 |
Why?
|
| Amygdala | 1 | 2012 | 159 | 0.380 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 2 | 2022 | 5 | 0.360 |
Why?
|
| Glutamine | 2 | 2019 | 45 | 0.340 |
Why?
|
| Corpus Striatum | 1 | 2011 | 278 | 0.340 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 237 | 0.340 |
Why?
|
| Hippocampus | 1 | 2012 | 471 | 0.330 |
Why?
|
| Middle Aged | 10 | 2021 | 21119 | 0.310 |
Why?
|
| Gyrus Cinguli | 4 | 2019 | 113 | 0.310 |
Why?
|
| Heterozygote | 2 | 2018 | 174 | 0.300 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2017 | 109 | 0.290 |
Why?
|
| Adolescent | 11 | 2019 | 8903 | 0.270 |
Why?
|
| Pharmacogenetics | 2 | 2016 | 47 | 0.250 |
Why?
|
| Antipsychotic Agents | 2 | 2017 | 247 | 0.250 |
Why?
|
| Nerve Net | 2 | 2018 | 180 | 0.240 |
Why?
|
| Gene Frequency | 2 | 2016 | 207 | 0.220 |
Why?
|
| Cartilage Oligomeric Matrix Protein | 1 | 2021 | 2 | 0.210 |
Why?
|
| Checklist | 1 | 2022 | 76 | 0.200 |
Why?
|
| Ventral Striatum | 1 | 2020 | 5 | 0.200 |
Why?
|
| Appointments and Schedules | 1 | 2021 | 47 | 0.190 |
Why?
|
| Case-Control Studies | 3 | 2019 | 1548 | 0.190 |
Why?
|
| Elective Surgical Procedures | 1 | 2021 | 95 | 0.190 |
Why?
|
| Anesthesia, General | 1 | 2021 | 86 | 0.190 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 3256 | 0.190 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 648 | 0.180 |
Why?
|
| DNA Methylation | 1 | 2021 | 192 | 0.180 |
Why?
|
| Behavior, Addictive | 3 | 2019 | 317 | 0.180 |
Why?
|
| Aspartic Acid | 2 | 2019 | 65 | 0.180 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 1851 | 0.180 |
Why?
|
| Alcohol Abstinence | 1 | 2019 | 23 | 0.170 |
Why?
|
| Homozygote | 2 | 2016 | 119 | 0.170 |
Why?
|
| Glycine | 1 | 2019 | 89 | 0.170 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2019 | 57 | 0.170 |
Why?
|
| Avoidance Learning | 1 | 2019 | 58 | 0.170 |
Why?
|
| Binge Drinking | 1 | 2019 | 50 | 0.170 |
Why?
|
| Sialoglycoproteins | 1 | 2018 | 24 | 0.160 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2017 | 10 | 0.160 |
Why?
|
| Minisatellite Repeats | 1 | 2017 | 16 | 0.160 |
Why?
|
| Hemodynamics | 1 | 2021 | 705 | 0.160 |
Why?
|
| Frontal Lobe | 1 | 2019 | 156 | 0.160 |
Why?
|
| Self-Control | 1 | 2017 | 9 | 0.150 |
Why?
|
| Transferrin | 1 | 2018 | 94 | 0.150 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1465 | 0.150 |
Why?
|
| Drug Interactions | 1 | 2018 | 289 | 0.150 |
Why?
|
| Double-Blind Method | 2 | 2019 | 1737 | 0.150 |
Why?
|
| Recurrence | 3 | 2020 | 948 | 0.150 |
Why?
|
| Adolescent Behavior | 1 | 2019 | 264 | 0.140 |
Why?
|
| Single-Blind Method | 1 | 2017 | 249 | 0.140 |
Why?
|
| Impulsive Behavior | 1 | 2017 | 85 | 0.140 |
Why?
|
| Central Nervous System Depressants | 1 | 2017 | 182 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 517 | 0.140 |
Why?
|
| Visual Perception | 1 | 2017 | 124 | 0.140 |
Why?
|
| Self Administration | 1 | 2017 | 419 | 0.140 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2016 | 87 | 0.140 |
Why?
|
| Attention | 1 | 2018 | 225 | 0.140 |
Why?
|
| Surveys and Questionnaires | 3 | 2016 | 2798 | 0.130 |
Why?
|
| Receptors, GABA-A | 1 | 2016 | 89 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1054 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.130 |
Why?
|
| Biomarkers | 2 | 2018 | 1593 | 0.130 |
Why?
|
| Prognosis | 2 | 2017 | 2093 | 0.130 |
Why?
|
| Sex Factors | 1 | 2018 | 1265 | 0.130 |
Why?
|
| Pilot Projects | 2 | 2019 | 1341 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2018 | 3702 | 0.120 |
Why?
|
| Varenicline | 1 | 2014 | 98 | 0.120 |
Why?
|
| GABA Modulators | 1 | 2013 | 26 | 0.110 |
Why?
|
| Phenotype | 1 | 2016 | 946 | 0.110 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 13 | 0.110 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 128 | 0.110 |
Why?
|
| Basal Ganglia | 1 | 2012 | 45 | 0.110 |
Why?
|
| Patient Selection | 1 | 2016 | 592 | 0.110 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 103 | 0.110 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2012 | 137 | 0.100 |
Why?
|
| Secondary Prevention | 1 | 2013 | 291 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 160 | 0.100 |
Why?
|
| Opioid-Related Disorders | 1 | 2015 | 298 | 0.100 |
Why?
|
| Functional Laterality | 1 | 2012 | 240 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 546 | 0.100 |
Why?
|
| Tobacco Use Disorder | 1 | 2015 | 432 | 0.090 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 504 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 329 | 0.090 |
Why?
|
| Protein Binding | 1 | 2012 | 1027 | 0.090 |
Why?
|
| Linear Models | 1 | 2011 | 521 | 0.090 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 2 | 2019 | 27 | 0.090 |
Why?
|
| Alleles | 2 | 2020 | 386 | 0.070 |
Why?
|
| Gene Expression | 1 | 2008 | 770 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 929 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 2077 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2022 | 62 | 0.050 |
Why?
|
| Aged | 1 | 2018 | 14842 | 0.050 |
Why?
|
| Animals | 2 | 2016 | 20877 | 0.050 |
Why?
|
| Photic Stimulation | 1 | 2019 | 229 | 0.040 |
Why?
|
| Oxygen | 2 | 2009 | 386 | 0.040 |
Why?
|
| Memory, Short-Term | 1 | 2018 | 79 | 0.040 |
Why?
|
| Reaction Time | 1 | 2018 | 170 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 370 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2016 | 55 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 346 | 0.030 |
Why?
|
| Taurine | 1 | 2014 | 51 | 0.030 |
Why?
|
| Valproic Acid | 1 | 2014 | 93 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 1860 | 0.030 |
Why?
|
| Neuroimaging | 1 | 2014 | 122 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 159 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2016 | 2264 | 0.020 |
Why?
|
| Cannabinoids | 1 | 2009 | 90 | 0.020 |
Why?
|
| Dronabinol | 1 | 2008 | 84 | 0.020 |
Why?
|
| Genomics | 1 | 2008 | 167 | 0.020 |
Why?
|
| Child | 1 | 2018 | 6400 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2009 | 689 | 0.020 |
Why?
|